COMP <GO>
RIGL vs JNJ // GROSS PROFIT MARGIN
Rigel Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RIGL 8
— JNJ 3
▲ GROSS PROFIT MARGIN LEADER: RIGL
LAST: $51.45 (+1.40%) • MKT CAP: $961.1M
gross-margins
93.30%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RIGL VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RIGL | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 93.30% | 67.90% | +25.40 | RIGL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.20% | 25.50% | +2.70 | RIGL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.3x | 18.5x | -11.20 | RIGL | /valuation <GO> |
| Free Cash Flow Yield | 7.87% | 2.97% | +4.90 | RIGL | /fcf-yield <GO> |
| Operating Margin | 42.60% | 34.70% | +7.90 | RIGL | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | RIGL | /net-margins <GO> |
| Revenue Growth (YoY) | 64.10% | 6.00% | +58.10 | RIGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.64 | 5.59 | -1.95 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.4 | 62.1 | +2.28 | RIGL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $961.1M | $662.49B | -$661.53B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RIGL REV | JNJ REV | RIGL GROSS % | JNJ GROSS % | RIGL FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $294.3M | $94.19B | 93.3% | 67.9% | $75.7M | $19.70B |
| FY 2024 | $179.3M | $88.82B | 89.6% | 69.1% | $31.5M | $19.84B |
| FY 2023 | $116.9M | $85.16B | — | — | -$5.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RIGL // BETA —
JNJ // BETA 1.08